Company intelligence / Profile preview
AskBio
- Ownership
- Private
- Employees
- ~900
- Development stage
- Other
Overview
AskBio has a rapidly expanding pipeline of investigational AAV-based gene therapies targeting rare genetic diseases. Several proprietary vectors have entered clinical testing. The company leverages its platform to develop treatments aimed at erasing genetic diseases with ongoing clinical programs in neuromuscular and CNS indications. It is advancing multiple candidates through early to mid-stage clinical development[1][2][3][4][5][6].
- Therapeutic areas
- PulmonologyRare DiseasesNeurologyCardiovascular
- Modalities
- AAV (Adeno-associated virus) gene therapy vectorsProprietary cell line manufacturing process (Pro10™)Synthetic promoters and DNA technologyExtensive capsid library for gene delivery
- Industry
- Biotech
Drug pipeline
16 assets15 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on AskBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AskBio.